Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/QAD.0b013e3283112bb7 | DOI Listing |
Similar Publications
Design, synthesis and biological evaluation of pyrazolo[3,4-]pyridine derivatives as dual CDK2/PIM1 inhibitors with potent anti-cancer activity and selectivity.
J Biomol Struct Dyn
March 2025
Applied Organic Chemistry Department, National Research Center, Dokki, Egypt.
The discovery of novel, selective inhibitors targeting CDK2 and PIM1 kinases, which regulate cell survival, proliferation, and treatment resistance, is crucial for advancing cancer therapy. This study reports the design, synthesis, and biological evaluation of three novel pyrazolo[3,4-]pyridine derivatives (), confirmed spectral analyses. These compounds were assessed for anti-cancer activity against breast, colon, liver, and cervical cancers using the MTT assay.
View Article and Find Full Text PDFStructural Dynamics of OATP1A2 in Mediating Paclitaxel Transport Mechanism in Breast Cancer.
Nanotheranostics
March 2025
Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Vidya Vihar, Raebareli Road, Lucknow- 226025, Uttar Pradesh, India.
Breast cancer remains a significant global health challenge, with drug resistance and poor bioavailability of chemotherapeutic agents like paclitaxel (PTX) presenting obstacles to effective treatment. This study investigates the potential role of the Solute Carrier Organic Anion Transporter Polypeptide 1A2 (OATP1A2) in PTX transport using computational approaches. We employed computational modeling, molecular docking, and molecular dynamics (MD) simulations to elucidate the structural dynamics of OATP1A2 and its interaction with PTX.
View Article and Find Full Text PDFHigh-performance PBPK model for predicting CYP3A4 induction-mediated drug interactions: a refined and validated approach.
Front Pharmacol
February 2025
Department of Drug Discovery and Development, GenFleet Therapeutics (Shanghai) Inc., Shanghai, China.
Introduction: The cytochrome P450 enzyme 3A4 (CYP3A4) mediates numerous drug-drug interactions (DDIs) by inducing the metabolism of co-administered drugs, which can result in reduced therapeutic efficacy or increased toxicity. This study developed and validated a Physiologically Based Pharmacokinetic (PBPK) model to predict CYP3A4 induction-mediated DDIs, focusing on the early stages of clinical drug development.
Methods: The PBPK model for rifampicin, a potent CYP3A4 inducer, was developed and validated using human pharmacokinetic data.
MONSTROUS: a web-based chemical-transporter interaction profiler.
Front Pharmacol
February 2025
Department of Defense Biotechnology High Performance Computing Software Applications Institute, Telemedicine and Advanced Technology Research Center, Defense Health Agency Research and Development, Medical Research and Development Command, Frederick, MD, United States.
Transporters are membrane proteins that are critical for normal cellular function and mediate the transport of endogenous and exogenous chemicals. Chemical interactions with these transporters have the potential to affect the pharmacokinetic properties of drugs. Inhibition of transporters can cause adverse drug-drug interactions and toxicity, whereas if a drug is a substrate of a transporter, it could lead to reduced therapeutic effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.